

Institutional Biosafety Committee MEETING MINUTES

Institution: Old Dominion University

Meeting Date: October 28, 2025

Meeting Time: 1:00 PM

Meeting Type: Electronic Meeting to approve September 2025 IBC Meeting Minutes.

IBC Members Present:

.
Lesley Greene (IBC Chair)
Stacey Michael (IBC Vice-Chair)
Bruce Finlay (IBC Member/BSO)
Erin Purcell (IBC Member)
Shawn Sarauw (IBC Member)
Lisa Shollenberger (IBC Member/Animal Expert)

Quorum: Five members are required to conduct business. 6 voting members were present at the start of the meeting.

Other Individuals/Guests in Attendance:

Srivenkat Kosuri (Manager Compliance)

Call to Order: The IBC Electronically met to vote to approval of the September 2025 IBC Meeting Minutes.

Conflict of Interest: Attendees were reminded that they are required to disclose conflicts of interest with applications being reviewed.

Review & Approval of previous meeting minutes: Six voting members unanimously voted to approve September 2025 IBC meeting minutes.

Review of Prior Business: Final Approval of new protocols after revisions via DMR.

PI Name: Margie Mulholland, Ph.D.

Reference Number/Title: [2373421-1 - 25-012] Water testing

NIH Guidelines Section: N/A

Risk Assessment and Discussion:

Designated members reviewed risk assessment and approved the modifications of new protocol.

Training:

As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.

Occupational Health Representative review (if applicable):

None required.

Biosafety Level Assignment

BSL1

IBC Vote for minor revisions:

Total = 7; For = 7; Opposed = 0; Abstained = 0; Recused = 0

Designated Member Review (DMR)

Total = 3; For = 3; Opposed = 0; Abstained = 0; Recused = 0

New IBC Registrations

None.

Continuing Review of Protocols, Closures, and Amendments:

PI Name: Venkat Maruthamuthu, Ph.D.

Reference Number/Title: [1819618-23 - 21-013] Study of Adhesion in Mammalian Cells

NIH Guidelines Section: Section III-F

Risk Assessment and Discussion:

The committee reviewed risk assessment and approved the protocol to continue.

Training:

As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.

Occupational Health Representative review (if applicable):

None required.

Biosafety Level Assignment

BSL1 and BSL2

IBC Vote

Total = 7; For = 7; Opposed = 0; Abstained = 0; Recused = 0

PI Name: Lisa Shollenberger, Ph.D.

Reference Number/Title: [1822943-9 - 21-014] BIOL 440/540 Immunological Methods

NIH Guidelines Section: N/A

Risk Assessment and Discussion:

The committee reviewed risk assessment and approved the protocol to continue.

Training:

As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.

Occupational Health Representative review (if applicable):

None required.

Biosafety Level Assignment

BSL1

IBC Vote for minor revisions

Total = 7; For = 7; Opposed = 0; Abstained = 0; Recused = 0

PI Name: Sage Hawn, Ph.D.

Reference Number/Title: [2104054-11 - 23-017] IBC-Biological Correlates of Trauma-Related Self-Medication Processes

NIH Guidelines Section: N/A

Risk Assessment and Discussion:

The committee reviewed risk assessment and approved the protocol to continue.

Training:

As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.

Occupational Health Representative review (if applicable):

None required.

Biosafety Level Assignment

BSL1

IBC Vote

Total = 7; For = 7; Opposed = 0; Abstained = 0; Recused = 0

PI Name: Nawarathna, Dharmakeerthi, Ph.D.

Reference Number/Title: [1956206-8 - 22-012] Sensor Development for Biomarker Detection

NIH Guidelines Section: N/A

Risk Assessment and Discussion:

The amendment to add personnel was administratively reviewed and approved.

Training:

As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.

Occupational Health Representative review (if applicable):

None required.

Biosafety Level Assignment

BSL1

IBC Vote

N/A

New Business/Additional Topics:

IBC approved unanimously ODU Lentivirus SOPs .

IBC approved unanimously ODU SOPs with addition of Designated Member Review of Protocols after minor modification.

Review of Incidents: None

Inspections/Ongoing Oversight: None

Public Comments (If Any): None

Adjournment: The next meeting scheduled is on November 18, 2025, at 1 PM via a Zoom teleconference.